Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lexicon Pharmaceuticals
Biotech
Why Lexicon is in ‘good shape to go crazy’: CEO
Lexicon CEO Michael Exton told Fierce how he set the company's development and financial pathway "on a very different trajectory."
Will Maddox
May 13, 2026 10:50am
Not a straight line: Biotech finds resilience in tumultuous year
Oct 10, 2025 10:44am
Novo inks $1B deal for Lexicon’s preclinical obesity prospect
Mar 28, 2025 7:30am
Lexicon feels the pain as non-opioid data underwhelm investors
Mar 3, 2025 9:52am
Vincerx acquisition leads to C-suite shake-up—Chutes & Ladders
Jan 3, 2025 8:30am
BridgeBio, Ipsen, George Medicines and more—Chutes & Ladders
May 3, 2024 8:30am
